Genmab A/S

Equities

GMAB

DK0010272202

Real-time Estimate Cboe Europe Other stock markets 08:11:00 10/02/2026 GMT			5-day change	1st Jan Change
1,928.50 ^DKK	-0.16%		-7.58%	-4.71%

02-04	Goldman Sachs Lowers Price Target for Genmab to 1,793 Danish Kroner (from 1,880), Reiterates Neutral - BN	FW
02-04	Fitch Highlights Genmab's Antibody Oncology Leadership in Final Rating	MT

Transcript : Genmab A/S Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 02

Published on 12/03/2024 at 07:30 pm GMT

S&P Capital IQ

Presenter Speech
Jon Beake (Analysts)

Thank you for joining us for this session with Genmab. Delighted to be joined by CFO, Anthony Pagano, in a [ Danish ] back to back here. I see we're in. And I

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Genmab A/S

02-04	Goldman Sachs Lowers Price Target for Genmab to 1,793 Danish Kroner (from 1,880), Reiterates Neutral - BN	FW
02-04	Fitch Highlights Genmab's Antibody Oncology Leadership in Final Rating	MT
01-21	DNB Carnegie Upgrades Genmab to Buy, Raises PT	MT
01-21	Genmab Posts Higher Darzalex Net Sales in FY25	MT
01-21	Genmab Announces Net Sales of DARZALEX (daratumumab) for 2025	CI
01-21	Genmab: Darzalex Sales Reach Nearly $14.4 Billion in 2025 (Update)	FW
01-21	Genmab says net sales of Darzalex in 2025 $14,351 mln	RE
01-21	Genmab: Darzalex Sales Reach Nearly $14.4 Billion in 2025	FW
01-21	DNB Carnegie Upgrades Genmab to Buy (Hold), Raises Target Price to 2,235 Danish Kroner (from 1,985)	FW
01-20	BofA Lifts Genmab Price Target, Estimates on Expected 'Catalyst Rich' FY26	MT
01-19	SHB: Overreaction in the Market to Genmab's Epkinly Study	FW
01-19	Genmab's Phase 3 Study with Epcoritamab Fails to Meet Overall Survival Endpoint	FW
01-19	Genmab's Epcoritamab Improves Progression-free Survival in Lymphoma Patients, Phase 3 Data Shows	MT
01-16	Genmab A/S Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed Refractory Diffuse Large B-Cell Lymphoma	CI
01-16	AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma	CI
01-16	AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival	DJ
01-16	Genmab Says Epcoritamab Improves Progression-Free Survival in Phase 3 Lymphoma Study	MT
01-16	Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study	RE
01-16	Genmab says phase 3 trial for epcoritamab did not reach statistical significance	RE
01-16	Genmab's blood cancer drug fails main goal in late-stage study	RE
01-16	Genmab Stock Trading Halted, Pending Material News Release	MT
01-15	Jyske Bank Raises Genmab Target Price to 2,300 Danish Kroner (2,000), Reiterates Hold - BN	FW
01-14	Genmab A/S Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03:45 PM
01-08	UBS Raises Price Target for Genmab to 2,750 Danish Kroner (from 2,700), Reiterates Buy	FW
01-07	Genmab A/S Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	CI